U.S. researchers devised a genetic model that they said is 90% accurate in measuring the risk of recurrence in people who have early-stage colon cancer. They also found that the model helped identify anti-inflammatory drugs and other chemotherapy agents that seemed to cause marked changes in tumors. "These findings have important implications for individualizing therapy," the study's lead scientist said.

Full Story:

Related Summaries